New Angiogenesis Inhibitor May Be Effective Against a Broad Range of Cancers
June 7th 2010Researchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.
Read More